Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T
about
Chemotherapy for advanced non-small cell lung cancer in the elderly population50 Years of progress in the systemic therapy of non-small cell lung cancerIncreased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trialsVinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.Gemcitabine and Vinorelbine (GemVin) RegimenManagement of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapyGemcitabine for the treatment of advanced nonsmall cell lung cancerScope of nanotechnology in ovarian cancer therapeutics.Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer.Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum-based doublets.Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials.A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.Pharmacogenomics: a reality or still a promise?Comparing effectiveness with efficacy: outcomes of palliative chemotherapy for non-small-cell lung cancer in routine practice.Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patientsCombination therapy versus single agent chemotherapy in non-small cell lung cancer.The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer.Present and future of lung cancer vaccines.Supportive care in patients with advanced non-small-cell lung cancer.Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancerA randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer.Molecular predictors of chemotherapy response in non-small-cell lung cancer.Health-related quality of life questionnaires in lung cancer trials: a systematic literature reviewPhase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.Bevacizumab for the treatment of advanced non-small-cell lung cancer.Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small-cell lung cancer: a retrospective study.Refining the treatment of advanced nonsmall cell lung cancer.Vinorelbine for non-small cell lung cancer.Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development.Is gemcitabine cost effective in cancer treatment?Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment.
P2860
Q24186466-F95D6893-A5D5-411D-BECA-88963D7AD7CDQ27014978-500B51AA-CEB3-441F-AC49-FCAFCBBC94A6Q28533753-EFAFA50E-0B56-4E37-898E-DC9A6DBD3E30Q33375704-57EC7CAA-1030-48D8-A4E1-2C8D452B2667Q33751771-48DBD2F6-F368-4B6C-951E-F5E4B8BCCC72Q33774738-F4390119-ED00-4958-9EFE-9D3A5A8D0EE8Q33885578-FA96F975-CA41-45A3-9494-D9C6196EDA85Q33915997-7B4D3CA0-0C55-4140-9BE8-44167962BD5BQ34075216-185DCE8F-FDAC-4882-AC6B-3CA35334D843Q34307949-D2815168-E675-4DA8-BD6A-85AA77F9B909Q34589112-CFAF753D-6964-444B-96C0-A4DFF34899C8Q35111780-C922A07E-00A5-455D-9735-5566C521D89DQ35557605-116D476A-6E93-4D57-84D0-2B1CCF61A45FQ35565186-2009C726-3802-447B-9BAE-0C3320DD70A4Q35714504-6CC61AF3-4F2B-4727-8E04-A9262335E0C5Q35879879-D0743F7F-1DFB-4350-8883-350F6B287FB9Q35994209-1091E4AE-9F31-49F1-907B-409FC098ECE4Q36222050-3B06D5F6-71DC-4A00-BB4F-A4FB62D05495Q36448679-8C61730E-5339-4042-AC91-BFB0E07220E3Q36580586-72FC4101-50AE-4B18-AEE0-8F67C419A839Q36648391-1008DFA6-420D-4A13-91B1-EDFFD037E8C6Q36671666-673B6708-BE3F-46D2-9878-187152D50FFEQ36694349-D2BBED03-69CF-4605-B949-E5676FEC1026Q36695252-EFCA7FDD-B304-485A-B26E-C305BBCD7544Q36788450-27043B1E-8A34-43BD-9863-B02AFCCA0685Q36788498-F4534E23-552D-4E82-809D-1CD8921EFFCFQ36884830-2199A013-51D6-449A-A862-3CA344F2716FQ36927640-35033909-02D4-493C-8128-B9C1448A154CQ36975137-7D9EDE62-08A2-417C-B44D-70478119AB21Q37119462-15222977-2756-4E53-88A2-0CCE0A7880B5Q37159495-B6787C1C-282B-48EC-B865-B72E2C8F5BE9Q37566846-CCA97031-78F0-4DA6-8347-EC85F7289A7DQ37645169-9B21FB24-2E52-465D-B6F5-4872EDFE9252Q37720767-C4E9A63D-9935-43AC-85D2-06CC9BFFD7FFQ38032176-08D90CB5-AAC7-45F3-96E3-FB8B3071288FQ38190461-16D0AC5E-4869-4070-A8A7-59D3DADB93FAQ38417869-F154FA8F-4B3E-4799-9ECF-A98CE0EC46D4Q38602994-CB788C3F-3974-4F6E-9E83-E6A602C2D1F7Q43042833-52B2EDEC-912F-438C-9184-6C968B480BB5Q45260508-CC6A4836-3B3C-4F29-B34A-1AB88F32DB87
P2860
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Gemcitabine plus vinorelbine c ...... Institute of Canada Clinical T
@en
Gemcitabine plus vinorelbine c ...... Institute of Canada Clinical T
@nl
type
label
Gemcitabine plus vinorelbine c ...... Institute of Canada Clinical T
@en
Gemcitabine plus vinorelbine c ...... Institute of Canada Clinical T
@nl
prefLabel
Gemcitabine plus vinorelbine c ...... Institute of Canada Clinical T
@en
Gemcitabine plus vinorelbine c ...... Institute of Canada Clinical T
@nl
P2093
P356
P1476
Gemcitabine plus vinorelbine c ...... Institute of Canada Clinical T
@en
P2093
Alfonso Illiano
Andrea Bezjak
Brian Findlay
Ciro Gallo
Enzo Veltri
Frances A Shepherd
Francesco Perrone
Francovito Piantedosi
Giampietro Gasparini
Giovanni P Ianniello
P304
P356
10.1200/JCO.2003.06.099
P407
P577
2003-07-01T00:00:00Z